

RESEARCH

Open Access

Excitotoxin-induced caspase-3 activation and microtubule disintegration in axons is inhibited by taxol

Anna Elizabeth King^{1*}, Katherine Adriana Southam², Justin Dittmann¹ and James Clement Vickers¹

Abstract

Background: Axon degeneration, a key pathological event in many neurodegenerative diseases and injury, can be induced by somatodendritic excitotoxin exposure. It is currently unclear, however, whether excitotoxin-induced axon degeneration is mechanistically similar to Wallerian degeneration, which occurs following axon transection, but does not involve axonal caspase activation.

Results: We have used mouse primary cortical neurons at 9 days *in vitro*, in a compartmented culture model that allows separation of the axon from the soma, to examine the pathological cascade of excitotoxin-induced axon degeneration. Excitotoxicity induced by chronic exposure to kainic acid, resulted in axonal fragmentation, which was associated with activation of caspase-3 in the axonal compartment. To examine the role of microtubules in these events, the microtubule-stabilizing agent, taxol, was added to either the axonal or somatodendritic compartment. Our results demonstrated that microtubule stabilization of axons resulted in a significant reduction in the number of fragmented axons following excitotoxin exposure. Interestingly, taxol exposure to either the somatodendritic or axonal compartment resulted in reduced caspase-3 activation in axons, suggesting that caspase activation is a downstream event of microtubule destabilization and involves signalling from the cell soma.

Conclusion: These data suggest that excitotoxin-induced axon degeneration shows some mechanistic differences to Wallerian degeneration, and that microtubule stabilization may assist in protecting nerve cells from excitotoxic effects.

Keywords: Axon degeneration, Caspase, Excitotoxicity, Taxol, Microtubule

Background

Axon pathology is a feature of many neurodegenerative diseases recently reviewed in [1] and following brain trauma [2]. The causes of axon pathology and degeneration in specific disease and injury conditions is currently unknown and may arise from a variety of insults. However, there is general consensus that axon degeneration can arise independently of cell death [3,4]. In this respect, several studies have shown that somal protection in disease models may fail to protect the axons from degeneration and this is a potential cause of lack of beneficial clinical outcomes for many therapeutic agents despite obvious rescue from neuronal loss [5,6]. Two

causes of axonal degeneration have been well documented in the literature. The first is axon transection, which results in complete disconnection of the distal axon from the soma and proximal axon regions, and the second is developmental axon pruning, which occurs during establishment of neuronal circuitry [7] and in cell culture is often modelled by growth factor withdrawal in dorsal root ganglion (DRG) neurons [8].

It has been well established that, following axon transection, the distal axon segment undergoes a cascade of stereotypical degenerative alterations, termed Wallerian degeneration. Much of what we know about Wallerian degeneration comes from the discovery of the *Wlds* mouse, which undergoes delayed Wallerian degeneration following peripheral axon transection, reviewed in [9,10]. This mouse expresses an abnormal fusion protein resulting from the splicing of two mRNAs which encode

* Correspondence: kingae@utas.edu.au

¹Wicking Dementia Research and Education Centre, University of Tasmania, Private Bag 23, Hobart, Tasmania 7000, Australia

Full list of author information is available at the end of the article

Nmnat1 (an NAD⁺ salvage enzyme) and the N-terminal protein of Ube4b (an E4 ubiquitin ligase) [11]. Although Wlds is protective in models of axonal severing [9] and a number of other disease models [12-14], it fails to protect against all forms of axonal degeneration in disease models [15-17] and does not protect against axon degeneration that occurs in developmental axon pruning [18]. Recent studies have highlighted other differences between Wallerian degeneration and developmental axon pruning, despite both being characterized morphologically by axonal beading and fragmentation. Simon et al. [8] demonstrated differences in proteolytic cascades in these types of degeneration, with developmental pruning being associated with axonal caspase-3 activation, through the mitochondrial activation of caspase-9. Caspase-3 activation is not involved in Wallerian degeneration [3,8]. Differences have also been demonstrated in the spatial activation of kinase pathways in these two forms of axon degeneration [19].

Axon degeneration in neurological disease is rarely associated with direct axonal severing and it is, thus, pertinent to investigate other potential causes of axon degeneration. Determining the pathological cascade within the axon will aid in developing therapeutic agents that will preserve axon integrity and function. Our previous studies and those of others, have demonstrated that both somatodendritic and axonal insults can result in a pathological cascade of axon degeneration *in vivo* and *in vitro* [20-27]. Of potential relevance to a number of neurodegenerative conditions, we have shown that chronic somatodendritic excitotoxin exposure in cultured cortical neurons results in degeneration of the unexposed axon [27]. Aberrant excitatory activity, including excitotoxicity, has been implicated in a number of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple sclerosis (MS), stroke, epilepsy and CNS trauma [28-31] many of which are characterized by extensive axonal degeneration [32,33], suggesting that excitotoxic mechanisms may contribute to axonal pathology in these conditions.

Axon degeneration following excitotoxicity in cultured cortical neurons has been characterized morphologically by axonal beading and fragmentation, sharing similarities with Wallerian degeneration and axon pruning. Axon degeneration involves a breakdown of the neuronal cytoskeleton, including microtubule depolymerisation [20] and early loss of neurofilament proteins [21] prior to frank destruction/dissolution of microtubules [20,21]. Microtubules are highly dynamic molecules capable of depolymerization at the ends (dynamic instability) and subject to severing along their length. These properties allow rapid growth and disassembly, which is essential for their role in cell division, motility, morphology and transport. The clear organization of MTs throughout the cell, their large surface area, polar configuration, highly

dynamic properties and role in transport makes them an ideal candidate for the spatial organization of signal transduction molecules within different parts of the cell [34]. The role that microtubule stability plays in axon degeneration and, in particular, whether microtubule breakdown is a downstream process resulting from activation of proteolytic cascades or has a more active role in the onset of degradation, is currently unclear.

Therefore, in this *in vitro* study using cultured mouse cortical neurons, we have investigated axon degeneration following excitotoxicity induced by kainic acid to determine mechanistic similarities to other forms of axon degeneration. Utilizing compartmented microfluidic chambers that allow spatial separation and manipulation of the soma and axons, we have investigated the role of microtubule destabilization in subsequent axonal and dendritic pathology in relation to excitotoxicity, in addition to the potential role of activation of apoptotic cascades within the axon. Our study indicates that kainic acid induced axon degeneration involves the activation of caspase-3 within the axon compartment and is inhibited by stabilization of the axonal microtubule network. Our data suggests that excitotoxin induced axon degeneration shares features of both Wallerian degeneration and developmental axon pruning.

Methods

Preparation of microfluidic chambers

Microfluidic chamber (Figure 1) were prepared as described previously [27]. Briefly, chambers were sterilized in ethanol, dried and attached to 22 mm² glass coverslips (Marienfeld). Poly-L lysine substrate (0.001%, Gibco) was loaded into both sides of the chamber and left overnight. Substrate was removed and chambers were filled with cell plating media consisting of Neurobasal media (Gibco), 2% B27 supplement (Gibco), 0.5 mM glutamine, 25 μM glutamate, 10% fetal calf serum (Gibco) and 1% antibiotic/antimycotic (Gibco). Chambers were equilibrated for a minimum of 4 hours prior to culture.

Primary cell culture

Primary mouse cortical cell culture was performed as we have described previously [27,35]. Briefly, cortical tissue was dissected from E15.5 mouse embryos and dissociated using 0.0125% trypsin (5 minutes at 37°C). Tissue was washed in cell plating media followed by mechanical titration using a 1 ml pipette. Cell viability and density was assessed using a trypan blue exclusion assay. Cell concentration was adjusted to 8×10⁶ cells/ml. Media was removed from the wells of the microfluidic chambers and 20 μl cells were loaded into one side of the microfluidic chambers (somatodendritic chamber). Cells were allowed to adhere to the substrate for 15 minutes prior to filling chambers with cell plating media. The




Figure 1 Timecourse of axonal and dendritic alterations following somatodendritic exposure to kainic acid. Top panel show schematic of neuronal arrangement in microfluidic chambers. β -III tubulin (axonal) and MAP2 (dendrite) immunoreactivity indicated beading of a small number of both distal axons and distal dendrites by 1 hour post exposure to kainic acid. By 6 hours extensive axonal beading was present and dendritic arbours were reduced in area. By 16 hours axons were fragmented, although β -III tubulin immunoreactivity was still present within axonal fragments and MAP2 immunoreactivity was restricted to neuronal soma and a small number of short dendrites. Arrows indicate beading; arrow head indicates shortened dendrites. Scale bar: 20 μ m.

following day, media was changed to cell maintenance media consisting of plating media without the fetal calf serum and glutamate. Cells were grown in 5% CO₂ at 37°C.

Pharmacological manipulation

Cells were treated with 100 μ M kainic acid or vehicle control at 9 days *in vitro* (DIV) corresponding to a time of dense axonal growth in the axon chamber. For taxol treatments, 3 μ g/ml taxol (in a maximum of 0.1% DMSO) or DMSO vehicle control (0.1%) was added to the axonal or somatodendritic chamber at the time of treatment with kainic acid.

Immunohistochemistry

Cell cultures were fixed in 4% paraformaldehyde prior to immunolabelling. Primary antibodies including activated

caspase-3 (Millipore, 1:200), β -III tubulin (Promega, 1:1000) and MAP2 (Millipore, 1:1000) were diluted in 0.3% triton-X (Fluka) and applied for 1 hour at room temperature and overnight at 4°C. Isotype and species specific secondary antibodies were applied at 1:1000 for 2 hours at room temperature. The nuclear stain DAPI was applied at for 15 minutes at room temperature.

Live cell imaging and quantitation

Taxol toxicity

To determine taxol toxicity, propidium iodide was applied to live cultures for 5 minutes prior to imaging on a Leica (DM LB2) fluorescent upright microscope fitted with a 40 \times dipping lens. Propidium iodide labelling in the nucleus (indicating loss of cell viability) was quantitated in 100 neuronal cells (identified by morphological characteristics under light microscopy) in randomly selected fields of view.

Axon fragmentation

Live images of axons were acquired on a Nikon TiE motorized inverted microscope, with chambers maintained at 37°C. For quantitation of axonal degeneration, images were acquired of the axonal compartment prior to cell treatments and from identical areas at 16 hours after treatments. A 3X3 square grid was placed over images (total area 0.2 mm²) and the percentage of fragmented or intact axons was quantitated by an observer blinded to conditions. Numbers of fragmented axons were normalized to pre-treatment counts for individual images giving a reliable quantitation of change in axonal fragmentation. Three images for each coverslip were taken for quantitation and a minimum of n = total of 5 coverslips from 3 separate culture days were used for all analysis except the dose response data where n = total of 3 coverslips across 3 separate cultures.

Dendritic arbour size

To determine dendritic arbour length, treated and fixed chambers (n = total of 4 coverslips across 3 separate cultures) were immunolabelled with MAP2 and labelled with the nuclear stain DAPI. Six images were acquired from randomly selected fields of the somatodendritic compartment on a Leica (DM LB2) fluorescent upright microscope with a 40 \times objective. Acquisition parameters were constant between data sets. Dendritic arbourization was quantitated in ImageJ using the NeuriteTracer plugin using standard protocols, with thresholds constant between data sets for individual experiments.

Caspase quantitation

Caspase quantitation was performed on n = 5 coverslips from 3 separate cultures. Treated and fixed cultures

were immunolabelled with an anti-activated caspase-3 antibody and 6 images were acquired from randomly selected fields of view of the axon compartment on a Leica (DM LB2) fluorescent upright microscope with a 40× objective. Positive labelling was selected from background using the threshold function of ImageJ with values constant between data sets. Area of positive immunoreactivity, as a proportion of total area was quantitated using ImageJ.

Statistical analysis

All statistical analysis and graphs were prepared in graphpad Prism (6.0) using one-way Anova with Bonferroni Post-hoc tests. $P < 0.05$ was considered significant.

Results

Somatodendritic kainic acid exposure induced axonal and dendritic cytoskeletal alterations

We have previously described morphological changes to axons following somatodendritic glutamate exposure [27]. To determine the sequence of cytoskeletal changes in the axons of mouse cortical neurons exposed to kainic acid in the somatodendritic compartment, treated (100 μ M kainic acid) and untreated cultures were fixed over a timecourse of 1, 6 and 16 hrs and labelled with antibodies against neuron-specific β -III tubulin or the dendrite specific microtubule associated protein MAP2. Loss of MAP2 immunoreactivity in dendrites has been shown previously to be an early feature of excitotoxicity and other insults [35]. In untreated cultures, β -III tubulin was present throughout the axons with occasional bebbing in the axon (Figure 1). At 1 hour post exposure to kainic acid, there was a distinct beading of the distal terminals of many axons in the axon chambers (Figure 1). MAP2 immunoreactivity demonstrated that beading was also present in distal dendritic arbours (Figure 1). At 6 hours following kainic acid exposure, β -III tubulin immunoreactivity demonstrated increased beading throughout the axon. MAP2 immunolabelling demonstrated loss of immunoreactivity in dendritic arbours at this stage relative to untreated cultures (Figure 1). By 16 hours, extensive axon fragmentation had occurred and β -III tubulin was highly beaded and fragmented, but still present in axonal fragments (Figure 1). MAP2 immunoreactivity in dendritic arbours following 16 hours kainic acid exposure was restricted to the soma and short lengths of dendrite (Figure 1).

Kainic acid induced axon fragmentation involved destabilization of axonal microtubules, which was rescued by axonal taxol exposure

Our data showed that axon fragmentation and microtubule alterations are an early feature of excitotoxin induced axon degeneration. We next determined if preventing microtubule destabilization with the drug taxol, would rescue the


axon from fragmentation. Initial investigations demonstrated that taxol concentrations of 1-3 μ g/ml did not cause neuronal death over a period of 24 hours. However concentration of 10 μ g/ml taxol caused some loss of nuclear membrane integrity, demonstrated by uptake of propidium iodide, indicating cell death (data not shown). For subsequent experiments, 3 μ g/ml taxol or vehicle control was added to the somatodendritic or axonal compartment at the time of addition of kainic acid or vehicle to the somatodendritic compartment. Axon degeneration (fragmentation) was quantitated at 16-18 hrs post kainic acid treatment. Axonal or somatodendritic application of taxol alone did not cause a significant increase in axonal fragmentation in these cultures (Figure 2a). Kainic acid induced a significant ($p < 0.05$) increase in axon fragmentation ($41.3 \pm 8.6\%$, mean \pm SEM) relative to vehicle-treated cultures ($4.4 \pm 2.9\%$, mean \pm SEM, Figure 2b). Application of taxol to the somatodendritic compartment did not significantly alter the percentage of fragmented axons ($25.8 \pm 5.2\%$, mean \pm SEM, Figure 2b) induced by kainic acid, although there was a trend towards reduction. However, axonal exposure to taxol resulted in a significant protection of the axon with reduced axonal fragmentation ($12.2 \pm 2.3\%$, mean \pm SEM) relative to kainic acid treated axons treated with vehicle alone (Figure 2b). These data indicate that taxol protects the axon directly by preventing microtubule destabilization within this compartment and that somatodendritic microtubule stabilization does not significantly prevent axon degeneration. To determine the concentration range that taxol is able to provide axonal protection against fragmentation, kainic acid treated cultures were exposed to axonal taxol from 10-1000 ng/ml. Axonal fragmentation was significantly reduced with 100 ng/ml taxol, while 10 ng/ml showed a non-significant trend towards reduced fragmentation (Figure 3).

Stabilization of microtubules in the somatodendritic or axonal compartment does not prevent loss of dendritic MAP2


Similar to axonal microtubule destabilization, alterations to MAP2 are an early feature of excitotoxin-induced axon degeneration. We next examined whether taxol protection in either the axonal or somatodendritic compartment prevented loss of MAP2 immunoreactivity in dendrites following kainic acid exposure. Application of taxol to either the axonal or somatodendritic compartment did not protect the neuron from loss of MAP2 immunoreactivity following kainic acid exposure (Figure 4).

Kainic acid induced axon degeneration involved activation of caspase-3 in the unexposed axonal segment


Cytoskeletal degradation can involve activation of proteolytic cascades. We investigated if axonal caspase activation was involved in axon degeneration following




kainic acid exposure. Immunocytochemical analysis with an antibody against activated caspase-3 demonstrated that exposure to kainic acid resulted in induction of active caspase-3 in axons at 16–18 hours post treatment (Figure 5a,b). Immunoreactivity was present as regularly spaced puncta along the length of the axon and was present in axons in both the axonal and somatodendritic



chambers. Caspase immunoreactivity was not present in MAP2 immunoreactive dendrites. To determine the staging of activation of caspase-3 following kainic acid exposure, cultures were treated and fixed over a timecourse of 1 and 6 hours. Increased numbers of caspase immunoreactive axons were not present at 1 hour post kainic acid exposure (Figure 5a). At 6 hours following kainic acid exposure there was a non-significant trend towards increase in caspase activation,





which was variable between cultures, indicating that caspase activation occurs at a later stage of the degenerative process.

Microtubule destabilization following kainic acid exposure is upstream of caspase activation

We next determined if axonal caspase activation occurred prior to, or resulted from, microtubule destabilization. Kainic acid-treated cultures were co-incubated with taxol in the axonal or somatodendritic compartments (as described above) and fixed after 16–18 hours. Immunolabelling with active caspase-3 demonstrated that axonal taxol prevented kainic acid induced activation of caspase-3 in the axonal compartment with a significant reduction in caspase immunofluorescence in taxol-treated cultures ($51.3 \pm 14.7 \times 10^{-3}\%$ of total area, mean ± SEM) relative to cultures exposed to kainic acid in the absence of axonal taxol ($227.9 \pm 24.5 \times 10^{-3}\%$ of total area, mean ± SEM Figure 5b,c). This suggests that caspase 3 activation occurs downstream of microtubule destabilization in the axon compartment. Interestingly,

somatodendritic taxol application also significantly reduced activation of caspase-3 by kainic acid ($28.5 \pm 8.8 \times 10^{-3}\%$ of total area, mean ± SEM), (Figure 5b,c) suggesting that somatodendritic signalling is involved in the activation of caspase in the axon.

Discussion

Our previous studies and those of others have demonstrated that excitotoxicity can induce axon degeneration. However, the relationship between excitotoxin-induced axon degeneration and other forms of axon degeneration remain unclear. In this study we have investigated whether excitotoxicity induces activation of axonal caspases as this has been implicated in developmental axon pruning, but is not involved in Wallerian degeneration following axon severing. Our study demonstrated that excitotoxicity results in activation of caspase-3 within the axon, suggesting a mechanistic difference to Wallerian-type degeneration. To investigate the relationship between cytoskeletal breakdown and caspase activation, we exposed cultures to excitotoxins in the presence or absence of the microtubule stabilizing agent, taxol, in the axonal or somatodendritic compartment, and examined the effect on axon fragmentation, axonal caspase activation and loss of dendritic MAP2. Our data demonstrated that application of axonal, but not somatodendritic, taxol, prevented axonal fragmentation. Furthermore both axonal and somatodendritic taxol prevented the activation of axonal caspase-3, although MAP2 loss was not altered. These data imply that caspase activation occurs downstream of microtubule destabilization within the axon and involves somal signalling.

Axonal caspase 3 activation in axon degeneration

Caspases are cysteine proteases that are important in mediating apoptosis. However, recently caspases have been implicated in other cellular processes that are not associated with cell death including synaptic [36] and axon [8,37,38] pruning. Caspase activation in the axon has been associated with a number of neurodegenerative diseases and condition. For example, axonal caspase has been associated with beta amyloid toxicity [37] and is found following injury [39]. Furthermore in models of Krabbes disease, which is caused by deficiency in galactosylsphingosine and characterized by demyelination, caspase activation in the axon, but not the soma, is present prior to demyelination [40]. These data suggest that axonal caspase activation in these conditions represents a type of axon degeneration that is different from classical Wallerian degeneration.

Despite these finding the axonal role of caspases remain unclear. Caspases have a number of substrates, including cytoskeletal proteins, which could account for

their activation. Both precaspase-3 and biochemically active caspase-3 have been shown to be present in healthy axons of cultured neurons [38] although the epitope of active caspase-3 may be masked by binding to apoptosis inhibitors as it can not be detected by immunohistochemistry. However, active caspase-3 immunoreactivity was localized to tubulin aggregates following nerve growth factor withdrawal [38], suggesting release from their inhibitors during degeneration. This is consistent with our findings of punctate expression of active caspase-3 following excitotoxicity. Growth factor deprivation may be involved in axonal degeneration following excitotoxicity as excitotoxicity has been shown to disrupt axon transport mechanisms and can result in the disruption and cleavage of components of the dynein- dynactin complex [41]. These molecular motors are responsible for retrograde transport and signaling, thus specifically implicating reduced growth factor signaling from the axon terminal [41].

Caspase activation following growth factor withdrawal is eliminated by knockdown of Bax [37,38], although pan caspase inhibitors do not provide complete protection against axon degeneration [38]. In this respect, caspase activation may act in parallel with other axon degeneration pathways involving NAD⁺ in this model [38]. This is similar to our previous findings in which cortical neurons treated with glutamate underwent axon degeneration that was partially protected by pan caspase inhibitors [27]. This suggests that caspase activation is not the only axon degeneration mechanisms activated in these pathways and also fits with our current study demonstrating that preventing axonal caspase activation by application of somatodendritic taxol does not prevent axon fragmentation. Thus, although the role of caspase-3 activation in axon degeneration is unclear, it may not be critical to degeneration and alterations to microtubule proteins may be more important in axonal maintenance.

The role of microtubule destabilization in excitotoxicity induced axon degeneration

Microtubule fragmentation has previously been implicated in axonal degeneration mechanisms and was the earliest detectable change in axons following severing when examining cytoskeletal alterations [20]. Breakdown of the microtubule network in Wallerian degeneration involves the ubiquitin proteasome system. However, while this is an early event relative to cytoskeletal breakdown, the role of microtubule dynamics in the initial intracellular biochemical cascade that results in the breakdown of the cytosol, remain unclear. An early study demonstrated the protective role of microtubule stabilization with taxol on hippocampal neurons exposed to kainic acid, [42]. Similarly the microtubule stabilizing agent davunetide protects against

kainic acid excitotoxicity in hippocampal cells both *in vitro* and *in vivo* [43]. However in these studies taxol was globally applied to neurons and protection attributed to prevention of calcium influx through calcium permeable AMPA receptors [42]. The role of microtubules in the axonal compartment was not examined. Interestingly in our study, somatodendritic taxol did not significantly protect the unexposed axon compartment, although a trend to reduced fragmentation was observed. This may reflect differences in the neurons cultured or suggest that axonal taxol was also contributing to axonal protection in the previous study.

Recently protective effects of axonal taxol have been reported in neurons exposed to 3 hours glutamate, strengthening our current results and suggesting that microtubule destabilization is an early and upstream event in axon degeneration following excitotoxicity [41]. Similarly several studies have now demonstrated protective effects of microtubule stabilization or increased microtubule acetylation in other models involving axonal degeneration such as mutant tau induced axon degeneration [44-46] and models of ALS [47]. In this respect microtubule stabilization protects neurons from activation of cdk5 and subsequent tau hyperphosphorylation in a cell culture model of amyloid toxicity [48] again suggesting that microtubule destabilization is an upstream event. Similarly, studies looking at dendritic degeneration following NMDA insult demonstrate that microtubule stabilization is upstream of calpain activation and loss of MAP2, suggesting that loss of MAP2 is not the cause of microtubule destabilization in this instance [49]. However in our study somatodendritic microtubule stabilization did not prevent MAP2 loss following kainic acid exposure perhaps reflecting difference in the excitotoxic pathways activated or the length of exposure.

Although microtubule stabilization is protective against degeneration in a number of models, overstabilization of microtubules may also be detrimental as seen in cases of peripheral neuropathy in cancer patients treated therapeutically with taxol [50]. Furthermore mutations in small heatshock proteins in Charcot Marie tooth disease cause them to bind more strongly to microtubules and alterations in microtubule dynamics may be the cause of peripheral neuropathy in this disease. Thus precise balance in microtubule stability may be necessary to prevent axonal degeneration mechanisms.

Somal- axonal signaling in axon degeneration

The effect of compartment specific microtubule stabilization is of interest in the current study. We show that stabilization of axonal microtubules significantly reduced caspase-3 activation within the axon suggesting that microtubule destabilization is required for caspase activation. However,

the effect of somatodendritic taxol on axonal caspase activation suggests that axonal microtubule destabilization alone is not sufficient for caspase activation, but that signalling from the soma to axon may be involved. The nature of this signal is currently unclear, however a recent study by Chen and colleagues [19] demonstrated that following growth factor withdrawal, spatially distinct kinase pathways are activated that differentially affect axonal beading and degeneration. In particular GSK3 activation or transcriptional repression in the soma was sufficient to block axonal degeneration but not axonal beading, whereas ErbB and p38 inhibition in the axon prevented both beading and fragmentation [19]. These data suggest that axon and soma may regulate different aspects of axonal degeneration and that in our excitotoxicity model these may be regulated in part by microtubule dynamics. This strengthens the hypothesis that parallel degeneration pathways are involved in excitotoxin induced axon degeneration. Despite this, although an early event, microtubule stabilization is not sufficient to prevent cleavage of components of the dynein-dynactin complex [41].

Conclusion

The current study suggests that excitotoxin induced axon degeneration involves features of both Wallerian degeneration and growth factor withdrawal and that alteration in microtubule dynamics are an upstream event in axon degeneration. Further deciphering the alterations to microtubule dynamics in relation to their post translational modifications, binding of microtubule associated proteins and association with downstream signalling pathways will be important in providing effective therapeutic intervention in a number of degenerative diseases and conditions in the central nervous system.

Competing interest

The authors declare that they have no conflict of interest for this manuscript.

Authors' contributions

AK designed and performed the experiments, analysed data and drafted the manuscript. KS performed analysis on images from cultures. JD prepared microfluidic cultures. JV aided in study design and manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by the Motor Neuron Disease Research Institute of Australia, Alzheimer's Australia Research, National Health and Medical Research Council grant (APP1003931) and the JO and JR Wicking trust.

Author details

¹Wicking Dementia Research and Education Centre, University of Tasmania, Private Bag 23, Hobart, Tasmania 7000, Australia. ²Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7000, Australia.

Received: 8 July 2013 Accepted: 1 September 2013

Published: 9 September 2013

References

1. Adalbert R, Coleman MP: Axon pathology in age-related neurodegenerative disorders. *Neuropathol Appl Neurobiol* 2012, **10**(10):1365–2990.
2. Smith DH, Hicks R, Povlishock JT: Therapy development for diffuse axonal injury. *J Neurotrauma* 2013, **30**(5):307–323.
3. Finn JT, et al: Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. *J Neurosci* 2000, **20**(4):1333–1341.
4. Osterloh JM, et al: dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. *Science* 2012, **337**(6093):481–484.
5. Ferri A, et al: Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. *Curr Biol* 2003, **13**(8):669–673.
6. Gould TW, et al: Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. *J Neurosci* 2006, **26**(34):8774–8786.
7. Luo L, O'Leary DD: Axon retraction and degeneration in development and disease. *Annu Rev Neurosci* 2005, **28**:127–156.
8. Simon DJ, et al: A caspase cascade regulating developmental axon degeneration. *J Neurosci* 2012, **32**(49):17540–17553.
9. Lunn ER, et al: Absence of wallerian degeneration does not hinder regeneration in peripheral nerve. *Eur J Neurosci* 1989, **1**(1):27–33.
10. Wang JT, Medress ZA, Barres BA: Axon degeneration: molecular mechanisms of a self-destruction pathway. *J Cell Biol* 2012, **196**(1):7–18.
11. Mack TG, et al: Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. *Nat Neurosci* 2001, **4**(12):1199–1206.
12. Samsam M, et al: The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. *J Neurosci* 2003, **23**(7):2833–2839.
13. Howell GR, et al: Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. *J Cell Biol* 2007, **179**(7):1523–1537.
14. Mi W, et al: The slow Wallerian degeneration gene, Wlds, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. *Brain* 2005, **128**(Pt 2):405–416.
15. Vande Velde C, et al: The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease. *Neuromolecular Med* 2004, **5**(3):193–203.
16. Rose FF Jr, et al: The Wallerian degeneration slow (Wld(s)) gene does not attenuate disease in a mouse model of spinal muscular atrophy. *Biochem Biophys Res Commun* 2008, **375**(1):119–123.
17. Kariya S, et al: The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy. *Neurosci Lett* 2009, **449**(3):246–251.
18. Parson SH, Mackintosh CL, Ribchester RR: Elimination of motor nerve terminals in neonatal mice expressing a gene for slow wallerian degeneration (CS7BI/Wlds). *Eur J Neurosci* 1997, **9**(8):1586–1592.
19. Chen M, et al: Spatially coordinated kinase signaling regulates local axon degeneration. *J* 2012, **32**(39):13439–13453.
20. Zhai Q, et al: Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. *Neuron* 2003, **39**(2):217–225.
21. Chung RS, et al: Glutamate induces rapid loss of axonal neurofilament proteins from cortical neurons in vitro. *Exp Neurol* 2005, **193**(2):481–488.
22. King AE, et al: Excitotoxicity mediated by non-NMDA receptors causes distal axonopathy in long-term cultured spinal motor neurons. *Eur J Neurosci* 2007, **26**(8):2151–2159.
23. Underhill SM, Goldberg MP: Hypoxic injury of isolated axons is independent of ionotropic glutamate receptors. *Neurobiol Dis* 2007, **25**(2):284–290.
24. Saggú SK, et al: The spatiotemporal pattern of somal and axonal pathology after perikaryal excitotoxic injury to retinal ganglion cells: a histological and morphometric study. *Exp Neurol* 2008, **211**(1):52–58.
25. Saggú SK, et al: Wallerian-like axonal degeneration in the optic nerve after excitotoxic retinal insult: an ultrastructural study. *BMC Neurosci* 2010, **11**:p. 97.
26. Hou ST, et al: CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. *J Neurochem* 2009, **111**(3):870–881.
27. Hosie KA, et al: Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model. *ASN Neuro* 2012, **4**(1).

28. Palop JJ, et al: **Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.** *Neuron* 2007, **55**(5):697–711.
29. Bogaert E, d'Ydewalle C, Van Den Bosch L: **Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target.** *CNS Neurol Disord Drug Targets* 2010, **9**(3):p. 297–p. 304.
30. Mehta A, et al: **Excitotoxicity: bridge to various triggers in neurodegenerative disorders.** *Eur J Pharmacol* 2013, **698**(1–3):6–18.
31. Kostic M, Zivkovic N, Stojanovic I: **Multiple sclerosis and glutamate excitotoxicity.** *Rev Neurosci* 2013, **24**(1):71–88.
32. Vickers JC, et al: **Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system.** *Brain Res Bull* 2009, **80**(4–5):217–223.
33. King AE, Vickers JC: **Excitotoxicity and axon degeneration.** In *Handbook of neurotoxicity*. Edited by Guillemin G. New York: Springer Science; 2013 (Accepted).
34. Gundersen GG, Cook TA: **Microtubules and signal transduction.** *Curr Opin Cell Biol* 1999, **11**(1):81–94.
35. King AE, et al: **Localization of glutamate receptors in developing cortical neurons in culture and relationship to susceptibility to excitotoxicity.** *J Comp Neurol* 2006, **498**(2):277–294.
36. D'Amelio M, et al: **Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease.** *Nat Neurosci* 2011, **14**(1):69–76.
37. Nikolaev A, et al: **APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.** *Nature* 2009, **457**(7232):981–989.
38. Schoenmann Z, et al: **Axonal degeneration is regulated by the apoptotic machinery or a NAD⁺-sensitive pathway in insects and mammals.** *J Neurosci* 2010, **30**(18):6375–6386.
39. Chen XH, et al: **Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.** *Am J Pathol* 2004, **165**(2):357–371.
40. Smith B, et al: **Peripheral neuropathy in the twitcher mouse involves the activation of axonal caspase 3.** *ASN Neuro* 2011, **3**(4).
41. Fujiwara T, Morimoto K: **Cooperative effect of p150Glued and microtubule stabilization to suppress excitotoxicity-induced axon degeneration.** *Biochem Biophys Res Commun* 2012, **424**(1):82–88.
42. Furukawa K, Mattson MP: **Taxol stabilizes [Ca²⁺]_i and protects hippocampal neurons against excitotoxicity.** *Brain Res* 1995, **689**(1):141–146.
43. Zemlyak I, et al: **The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.** *J Neurochem* 2009, **111**(5):1252–1263.
44. Shemesh OA, Spira ME: **Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimetabolic drug paclitaxel.** *Neurobiol Dis* 2011, **43**(1):163–175.
45. Barten DM, et al: **Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.** *J Neurosci* 2012, **32**(21):7137–7145.
46. Xiong Y, et al: **HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.** *Proc Natl Acad Sci USA* 2013, **110**(12):4604–4609.
47. Taes I, et al: **Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS.** *Hum Mol Genet* 2013, **30**:30.
48. Li G, et al: **Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.** *J Neurochem* 2003, **84**(2):347–362.
49. Hoskison MM, Shuttlesworth CW: **Microtubule disruption, not calpain-dependent loss of MAP2, contributes to enduring NMDA-induced dendritic dysfunction in acute hippocampal slices.** *Exp Neurol* 2006, **202**(2):302–312.
50. Quasthoff S, Hartung HP: **Chemotherapy-induced peripheral neuropathy.** *J Neurol* 2002, **249**(1):9–17.

doi:10.1186/2051-5960-1-59

Cite this article as: King et al.: Excitotoxin-induced caspase-3 activation and microtubule disintegration in axons is inhibited by taxol. *Acta Neuropathologica Communications* 2013 1:59.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

